today announced that interim results from a Phase 2b study evaluating rindopepimut in newly-diagnosed glioblastoma multiforme sufferers were provided at the 46th Annual Meeting of the American Society of Clinical Oncology . Rindopepimut, an investigational immunotherapeutic vaccine that targets the tumor-specific molecule epidermal development factor receptor variant III , originated by Celldex Therapeutics and is licensed to Pfizer.They considered two groups regarded as at elevated risk: school-aged kids taking stimulants, which are often used to treat Interest Deficit Hyperactivity Disorder , and adolescents playing organized sports. The study team determined that every year of life saved would cost from $90,000 to $200,000 . Although there is no hard and fast series separating worthwhile and costly public health interventions, programs can be compared to get an basic notion of their value. For example, interventions that cost $90,000 to $200,000 per life calendar year saved are believed expensive, compared to other interventions, which frequently save lifestyle years at $50,000 to $100,000, or less even.